PMID- 22374482
OWN - NLM
STAT- MEDLINE
DCOM- 20130104
LR  - 20240426
IS  - 1432-0851 (Electronic)
IS  - 0340-7004 (Print)
IS  - 0340-7004 (Linking)
VI  - 61
IP  - 10
DP  - 2012 Oct
TI  - Cancerous HLA class I expression and regulatory T cell infiltration in gastric 
      cancer.
PG  - 1663-9
AB  - BACKGROUND: Since antitumor immune reactions between tumors and intratumoral 
      immunocytes have been verified in several human tumors, immunological therapeutic 
      strategies must be considered to obtain the proper efficacy of tumor shrinkage 
      under these conditions. Human leukocyte antigen (HLA) class I expression in 
      cancer cells and degree of infiltration of regulatory T cells (Tregs) in the 
      stroma have been regarded as important markers of antitumor immune reactions in 
      the context of independent immunological mechanisms. In the current study, we 
      investigated HLA class I expression and Treg cells infiltration in gastric cancer 
      and discussed the clinical implications of this combinatory analysis in gastric 
      cancer. PATIENTS AND METHODS: A total of 141 gastric cancer patients who received 
      R0 gastrectomy at Kagoshima University Hospital were studied. 
      Immunohistochemically, in 141 gastric cancer patients, HLA class I expression and 
      Treg cell infiltration in cancerous tissue were evaluated using HLA class I 
      (EMR8-5) and forkhead box p3 (FOXP3) monoclonal antibodies. The correlation 
      between clinical factors and tumor-infiltrating Treg cells was analyzed. RESULTS: 
      HLA class I expression was positively associated with depth of tumor invasion 
      (P < 0.05). Infiltration of Foxp3-positive cells did not correlate with any 
      clinicopathological markers. HLA class I expression had no association with Treg 
      cell infiltration (r = 0.04). A better postoperative outcome was associated with 
      fewer numbers of Treg infiltration (P = 0.034). A combination of HLA and Treg 
      analysis may lead to a more accurate prediction of postoperative outcome 
      (P = 0.02). CONCLUSIONS: Two different antitumor immunological markers, Treg 
      infiltration and HLA class I expression, affected clinicopathological factors in 
      gastric cancer by different mechanisms. Thus, an immunological combination of HLA 
      class I expression and Treg cell infiltration may more accurately predict 
      postoperative outcome. Immunological balance needs to be restored after 
      evaluation of each immunological deficit in gastric cancer.
FAU - Ishigami, Sumiya
AU  - Ishigami S
AD  - Department of Digestive Surgery, and Breast and Thyroid Surgery, Kagoshima 
      University School of Medicine, 8-35-1 Sakuragaoka, Kagoshima 890-8520, Japan. 
      ishiga@m.kufm.kagoshima-u.ac.jp
FAU - Arigami, Takaaki
AU  - Arigami T
FAU - Uenosono, Yoshikazu
AU  - Uenosono Y
FAU - Matsumoto, Masataka
AU  - Matsumoto M
FAU - Okumura, Hiroshi
AU  - Okumura H
FAU - Uchikado, Yasuto
AU  - Uchikado Y
FAU - Kita, Yoshiaki
AU  - Kita Y
FAU - Nishizono, Yuka
AU  - Nishizono Y
FAU - Maemura, Kosei
AU  - Maemura K
FAU - Kijima, Yuko
AU  - Kijima Y
FAU - Nakajo, Akihiro
AU  - Nakajo A
FAU - Owaki, Tetsuhiro
AU  - Owaki T
FAU - Ueno, Shinichi
AU  - Ueno S
FAU - Hokita, Shuichi
AU  - Hokita S
FAU - Natsugoe, Shoji
AU  - Natsugoe S
LA  - eng
PT  - Journal Article
DEP - 20120229
PL  - Germany
TA  - Cancer Immunol Immunother
JT  - Cancer immunology, immunotherapy : CII
JID - 8605732
RN  - 0 (Antigens, Neoplasm)
RN  - 0 (FOXP3 protein, human)
RN  - 0 (Forkhead Transcription Factors)
RN  - 0 (Histocompatibility Antigens Class I)
SB  - IM
MH  - Adenocarcinoma/*immunology/pathology/surgery
MH  - Aged
MH  - Antigens, Neoplasm/*immunology
MH  - Female
MH  - Forkhead Transcription Factors/immunology
MH  - Gastrectomy/methods
MH  - Histocompatibility Antigens Class I/*immunology
MH  - Humans
MH  - Lymphocytes, Tumor-Infiltrating/*immunology
MH  - Male
MH  - Middle Aged
MH  - Stomach Neoplasms/*immunology/pathology/surgery
MH  - T-Lymphocytes, Regulatory/*immunology
MH  - Treatment Outcome
PMC - PMC11028633
EDAT- 2012/03/01 06:00
MHDA- 2013/01/05 06:00
PMCR- 2012/02/29
CRDT- 2012/03/01 06:00
PHST- 2012/01/04 00:00 [received]
PHST- 2012/02/13 00:00 [accepted]
PHST- 2012/03/01 06:00 [entrez]
PHST- 2012/03/01 06:00 [pubmed]
PHST- 2013/01/05 06:00 [medline]
PHST- 2012/02/29 00:00 [pmc-release]
AID - 1225 [pii]
AID - 10.1007/s00262-012-1225-5 [doi]
PST - ppublish
SO  - Cancer Immunol Immunother. 2012 Oct;61(10):1663-9. doi: 
      10.1007/s00262-012-1225-5. Epub 2012 Feb 29.